MIRA Pharmaceuticals (MIRA) Projected to Post Earnings on Friday

MIRA Pharmaceuticals (NASDAQ:MIRA) is anticipated to post its results before the market opens on Friday, March 27th. Analysts expect MIRA Pharmaceuticals to post earnings of ($0.04) per share for the quarter.

MIRA Pharmaceuticals Stock Down 8.1%

Shares of NASDAQ MIRA opened at $1.02 on Friday. MIRA Pharmaceuticals has a twelve month low of $0.73 and a twelve month high of $2.45. The stock’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.39. The company has a market capitalization of $42.72 million, a PE ratio of -0.67 and a beta of 1.78.

Wall Street Analyst Weigh In

MIRA has been the topic of a number of recent analyst reports. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating on the stock. Wall Street Zen downgraded MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, MIRA Pharmaceuticals currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in MIRA Pharmaceuticals during the second quarter valued at $26,000. Creative Planning purchased a new stake in MIRA Pharmaceuticals in the second quarter worth $27,000. Two Sigma Investments LP raised its stake in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after buying an additional 25,816 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares during the period. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.